Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

• DOI: 10.6004/jnccn.2017.0007
• Publication Date: 2017-04-14T16:08:52Z
• Authors: Peter L. Greenberg; Richard M. Stone; Aref Al-Kali; Stefan K. Barta; Rafael Bejar; John M. Bennett; Hetty Carraway; Carlos M. De Castro; H. Joachim Deeg; Amy E. DeZern; Amir T. Fathi; Olga Frankfurt; Karin Gaensler; Guillermo Garcia-...; Elizabeth A. Grif...; David Head; Ruth Horsfall; Robert A. Johnson; Mark Juckett; Virginia M. Klimek; Rami Komrokji; Lisa A. Kujawski; Lori J. Maness; Margaret R. O'Don...; Daniel A. Pollyea; Paul J. Shami; Brady L. Stein; Alison R. Walker; Peter Westervelt; Amer Zeidan; Dorothy A. Shead; Courtney Smith
• Keywords: Clinical Practice

The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with highly variable disease course. Diagnostic criteria to better stratify patients MDS continue evolve, based on morphology, cytogenetics, and the presence cytopenias. More accurate classification will allow for treatment guidance. Treatment encompasses supportive care, anemia, low-intensity therapy, high-intensity therapy. This portion guidelines focuses diagnostic classification, molecular abnormalities, therapeutic options, recommended approaches.